 Glucagon-Like Peptide-1 Receptor
"Glucagon-Like Peptide-1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).
| Descriptor ID |
D000067757
|
| MeSH Number(s) |
D12.776.543.750.695.021.500 D12.776.543.750.750.360.100.500
|
| Concept/Terms |
Glucagon-Like Peptide-1 Receptor- Glucagon-Like Peptide-1 Receptor
- Glucagon Like Peptide 1 Receptor
- Peptide-1 Receptor, Glucagon-Like
- Receptor, Glucagon-Like Peptide-1
- GLP-1R Receptor
- GLP 1R Receptor
- Receptor, GLP-1R
- GLP1R Protein
- Protein, GLP1R
- GLP-1 Receptor
- GLP 1 Receptor
- Receptor, GLP-1
- GLP1R Receptor
- Receptor, GLP1R
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-1 Receptor".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-1 Receptor".
This graph shows the total number of publications written about "Glucagon-Like Peptide-1 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 7 | 7 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 4 | 4 | 8 | | 2018 | 3 | 2 | 5 | | 2019 | 2 | 2 | 4 | | 2020 | 4 | 4 | 8 | | 2021 | 2 | 2 | 4 | | 2022 | 1 | 3 | 4 | | 2023 | 0 | 3 | 3 | | 2024 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide-1 Receptor" by people in Profiles.
-
Shah VN, Peters AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs PG, Lal RA, Mader JK, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho CN, Ayers AT, Tian T, Aaron RE, Klonoff DC. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. J Diabetes Sci Technol. 2025 Jan; 19(1):191-216.
-
Choy K, Abbitt D, Kovar A, Jones TS, McCallum M, Thomas EA, Saxon DR, Wikiel KJ, Jones EL. Weighing your options-intragastric balloon versus semaglutide. Surg Endosc. 2024 Oct; 38(10):6070-6075.
-
Akhverdyan N, Wieland A, Sullivan S, Lindsay M, Swartwood S, Arndt G, Kaizer LK, Jensen T. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis. Metab Syndr Relat Disord. 2024 Oct; 22(8):608-618.
-
Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.
-
van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, Gordin D, Persson F, Rosas SE, Rossing P, Schaub JA, Tuttle K, Waikar SS, Heerspink HJL. Combination therapy for kidney disease in people with diabetes mellitus. Nat Rev Nephrol. 2024 07; 20(7):433-446.
-
Waldrop SW, Johnson VR, Stanford FC. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat Med. 2024 Jan; 30(1):22-25.
-
Park J, Ntelis S, Yunasan E, Downton KD, Yip TC, Munir KM, Haq N. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023 12 21; 109(1):279-292.
-
Leggio L, Hendershot CS, Farokhnia M, Fink-Jensen A, Klausen MK, Schacht JP, Simmons WK. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023 Dec; 29(12):2993-2995.
-
Salahuddin T, Hebbe A, Daus M, Essien UR, Waldo SW, Rodriguez F, Ho PM, Simons C, Gilmartin HM, Doll JA. Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021. Am Heart J. 2024 02; 268:68-79.
-
Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022 12; 36(12):108332.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|